http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 19 May 2026 16:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html <p align="justify">SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.’s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.</p> <p align="justify">To register for the conference, visit the <a href="https://www.globenewswire.com/Tracker?data=OOnUQrpGBOdiZA_ykhEnctREvewm_M_zeH5lgXKPTJ6PdAQhDS8guIMzgc_NnIbUMRt3gX6hHHphHejGuMSpIKyvPml9N5rcL7IRjAkmbyYYd3Qse30RWlLCqWbLG7kdTCVU5HstVwDGMjZOp1ithQoGQYWJi8EFlO9W4oFM5l593bnQ6QOR3xpef6LhlwqY" rel="nofollow" target="_blank"><u>A.G.P. Registration Link</u></a>.</p> <p http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Participate+in+A.G.P.%E2%80%99s+Annual+Virtual+Healthcare+Conference/26522100.html Tue, 19 May 2026 16:45:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Earnings/Dermira+%28DERM%29+Tops+Q1+EPS+by+5c/26487043.html <p>Dermira (NASDAQ: DERM) reported Q1 EPS of $0.02, $0.05 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $16 million versus the consensus estimate of $20.42 million.</p><p>For earnings history and earnings-related data on Dermira (DERM) <a href="http://www.streetinsider.com/ec_earnings.php?q=DERM">click here</a>.</p> http://www.streetinsider.com/Earnings/Dermira+%28DERM%29+Tops+Q1+EPS+by+5c/26487043.html Wed, 13 May 2026 16:45:32 -0400 DERM http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Journey+Medical+Corp++++++For%3A+Mar+31/26486825.html si-local-file:///var/storage/secattach/20260513/26486825.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Journey+Medical+Corp++++++For%3A+Mar+31/26486825.html Wed, 13 May 2026 16:34:00 -0400 DERM O.26057861 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Journey+Medical+Corp++++++For%3A+Mar+31/26486825.html si-local-file:///var/storage/secattach/20260513/26486825.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Journey+Medical+Corp++++++For%3A+Mar+31/26486825.html Wed, 13 May 2026 16:34:00 -0400 DERM O.26057861 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Journey+Medical+Corp++++++For%3A+May+13/26485921.html si-local-file:///var/storage/secattach/20260513/26485921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Journey+Medical+Corp++++++For%3A+May+13/26485921.html Wed, 13 May 2026 16:06:00 -0400 DERM O.26057861 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Journey+Medical+Corp++++++For%3A+May+13/26485921.html si-local-file:///var/storage/secattach/20260513/26485921.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Journey+Medical+Corp++++++For%3A+May+13/26485921.html Wed, 13 May 2026 16:06:00 -0400 DERM O.26057861 http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html <p align="center"><em>Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million </em></p> <p align="center"><em>Emrosi</em>^®<em> revenues were $6.3 million in the first quarter ended March 31, 2026</em></p> <p align="center"><em>Cash position increased to $27 million, driven by strong financial performance</em></p> <p align="center"><em>Company to hold conference call today at 4:30 p.m. ET</em></p> <p align="justify">SCOTTSDALE, Ariz., May 13, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+Reports+First+Quarter+2026+Financial+Results+and+Recent+Corporate+Highlights/26485657.html Wed, 13 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Press+Releases/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html <p><strong>Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET</strong></p><p align="justify">SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2026 financial results after the U.S. financial markets close on Wednesday, May 13, 2026. Journey Medical management will conduct a conference call and http://www.streetinsider.com/Globe+Newswire/Journey+Medical+Corporation+to+Announce+First+Quarter+2026+Financial+Results+on+May+13%2C+2026/26443253.html Wed, 06 May 2026 16:01:00 -0400 DERM DERM FBIO http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Journey+Medical+Corp+++++++++++++++++/26408135.html si-local-file:///var/storage/secattach/20260430/26408135.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Journey+Medical+Corp+++++++++++++++++/26408135.html Thu, 30 Apr 2026 16:12:00 -0400 DERM O.26057861 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Journey+Medical+Corp+++++++++++++++++/26408135.html si-local-file:///var/storage/secattach/20260430/26408135.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Journey+Medical+Corp+++++++++++++++++/26408135.html Thu, 30 Apr 2026 16:12:00 -0400 DERM O.26057861